Table 3. Pooled Results of Subgroup Analyses of Bullous Pemphigoid in Initiation of Second-generation Sulfonylurea and DPP-4 Inhibitor Use.

Characteristic	Sulfonylurea				DPP-4 inhibitor				HR (95% CI)
	No. of patients	No. of events	Person-years	IR per 1000 person-years	No. of patients	No. of events	Person-years	IR per 1000 person-years
Age, y
≥65	423 862	155	316 764	0.49	423 862	229	290 423	0.79	1.62 (1.32-1.99)
<65	399 989	26	269 975	0.10	399 989	26	286 052	0.09	0.94 (0.55-1.62)
Sex
Male	406 720	99	303 820	0.33	406 720	122	295 157	0.41	1.38 (1.06-1.79)
Female	424 850	96	290 818	0.33	424 850	124	287 548	0.41	1.34 (1.03-1.75)
Racea
White	208 960	86	158 099	0.54	208 960	128	138 181	0.93	1.70 (1.30-2.24)
Nonwhite	68 499	28	41 988	0.67	68 499	22	43 411	0.51	0.77 (0.44-1.34)
Individual drugs
Sitagliptin phosphate	654 923	136	464 464	0.29	654 923	156	448 105	0.35	1.15 (0.91-1.45)
Saxagliptin hydrochloride	123 216	20	93 256	0.21	123 216	25	86 928	0.29	0.97 (0.56-1.67)
Linagliptin	119 316	42	76 012	0.55	119 316	85	71 103	1.20	1.68 (1.16-2.43)

Abbreviations: DPP-4, dipeptidyl peptidase-4; HR, hazard ratio; IR, incidence rate.

^aAvailable in Medicare only.